科源製藥(301281.SZ):二甲雙胍是否有長壽的作用,公司未做相關的臨牀試驗
格隆匯6月9日丨科源製藥(301281.SZ)在投資者互動平台表示,公司既有鹽酸二甲雙胍原料藥,也有對應的製劑產品鹽酸二甲雙胍緩釋片。鹽酸二甲雙胍原料藥用於生產口服降糖製劑,製劑產品通過抑制肝葡萄糖的輸出,改善外周組織對胰島素的敏感性,增加對葡萄糖的攝取和利用,從而降低血糖。二甲雙胍適應症為用於單純飲食控制不滿意的Ⅱ型糖尿病病人,尤其是肥胖和伴高胰島素血癥者,雖然藥品説明書中介紹服用二甲雙胍可能有減輕體重的效果,但二甲雙胍是降糖類藥品,需要在醫生指導下使用。二甲雙胍是否有長壽的作用,公司未做相關的臨牀試驗,無法得出類似結論。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.